CAR T cell therapy offers a promising therapy option in various autoimmune disease. However, the risk−benefit evaluation in the context of autoimmune disorders has not been established yet and must be reconsidered, as certain complications are not tolerable in patients with autoimmune diseases.

As in most autoimmune disorders there is no well described antigen, the broad B-cell targeting procedure seems to be the most sensible approach at this timepoint. However, it is probably worth pursuing other options, such as CAR regulatory T cells (Treg), or allogenous CAR T cells.